We employ a long term, patient, company-build perspective with our portfolio, and we collaborate with management to do what is best over the long run for the company, and for patients. We provide capital through a company’s full risk cycle and over many years, whether the company is private or public. We actively reject the philosophy of exiting as quickly as possible. We believe this approach is consistent with the life cycle of our deals, provides optimal collaboration with our teams, and the opportunity for better financial returns and the incredible gratification of seeing innovative therapies reach patients.